{"id":"W2915372679","doi":"10.1016/j.bbmt.2019.02.014","title":"Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation","year":2019,"lang":"en","type":"review","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; University of Ottawa; Ottawa Hospital","funders":"National Institute of Allergy and Infectious Diseases; Pharmacyclics; Allergan; Mylan; National Institutes of Health; Genentech; Multiple Sclerosis Society; Biogen; Pfizer; Incyte; Bayer HealthCare; Acorda Therapeutics; Atara Biotherapeutics; Gilead Sciences; Sanofi; National Institute for Health and Care Research; Teva Pharmaceutical Industries; EMD Serono; Celgene; Novartis; Alexion Pharmaceuticals; Roche; Genzyme; Amgen; Chugai Pharmaceutical; MedDay Pharmaceuticals; GlaxoSmithKline","keywords":"Medicine; Transplantation; Clinical trial; Multiple sclerosis; Hematopoietic stem cell transplantation; Disease; Surgery; Oncology; Intensive care medicine; Internal medicine; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02136916,0.001176754,0.002283067,0.001763385,0.001429724,0.0042065,0.00413915,0.01544198,0.003049657],"category_scores_gemma":[0.03135588,0.0006387865,0.003228483,0.002071047,0.001511413,0.002986117,0.002586661,0.01532756,0.003184216],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002345477,"about_ca_system_score_gemma":0.02023096,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005793934,"about_ca_topic_score_gemma":0.007657319,"domain_scores_codex":[0.9925792,0.001933407,0.001690895,0.0006076666,0.002694286,0.0004946106],"domain_scores_gemma":[0.9741794,0.008164259,0.003562263,0.00054809,0.01042692,0.003119159],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003260957,0.0001221956,0.0006377779,0.005303917,0.0003431893,0.0001703482,0.000161669,0.0002277429,0.0009480473,0.003046206,0.8415158,0.1471969],"study_design_scores_gemma":[0.0006110882,0.0001809646,0.002025451,0.01848347,0.0008840277,0.0002546773,0.0001131727,0.0003297888,0.0006331116,0.005139893,0.9712749,0.00006948646],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"review","genre_scores_codex":[0.0009039894,0.2189175,0.001332771,0.676308,0.09455442,0.0006308383,0.001416813,0.00008740546,0.005848234],"genre_scores_gemma":[0.01063273,0.2994599,0.01135982,0.5401002,0.1195636,0.001669711,0.002288911,0.0002003998,0.0147247],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.02136916,"threshold_uncertainty_score":0.1130123,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07587259970366206,"score_gpt":0.3324805216397326,"score_spread":0.2566079219360706,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}